NCT04780165 is a NA clinical trial of Blephademodex in Demodex Blepharitis, sponsored by Laboratoires Thea.

Who is sponsoring NCT04780165?

NCT04780165 is sponsored by Laboratoires Thea.

What drugs are being tested in NCT04780165?

Interventions in NCT04780165: Blephademodex.

What condition does NCT04780165 study?

NCT04780165 studies Demodex Blepharitis.

Is NCT04780165 still recruiting?

NCT04780165 is currently completed. Last updated 3 March 2021.

Last reviewed 2021-03-03 · How we verify

NCT04780165

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Tolerability of Blephademodex Wipes

Completed NA Last updated 3 March 2021

What this trial tests

NA trial testing Blephademodex in Demodex Blepharitis in 50 participants. Completed in 14 May 2020.

Timeline

11 September 2019

Primary endpoint
13 March 2020

14 May 2020

Quick facts

Lead sponsor	Laboratoires Thea
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	11 September 2019
Primary completion	13 March 2020
Estimated completion	14 May 2020
Sites	1 location across Germany

Drugs / interventions tested

Blephademodex

Conditions studied

Demodex Blepharitis — all drugs for Demodex Blepharitis →

Sponsor

Laboratoires Thea — full company profile →

Who can join

Eligibility, any sex, with Demodex Blepharitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective \- To evaluate efficacy of Blephademodex eyelid hygiene wipe treatment with a subsequent maintenance period with Blephaclean lid cleansing wipes in Demodex blepharitis, as assessed by the change in ocular symptoms by a Global Discomfort Scale (GDS). Secondary Objectives * To evaluate the efficacy of Blephademodex eyelid hygiene wipe treatment in Demodex blepharitis as assessed by the change alone and in combination with a subsequent maintenance period of treatment with Blephaclean eyelid cleansing wipes ocular symptoms by: adapted TOSS; SANDE; specific blepharitis symptoms; Demodex count; ocular surface redness (Efron scale); lid margin redness/swelling (Efron / custom scale); Dandruff coverage at bases of eyelashes; ocular surface staining (Oxford scale; corneal only) * To evaluate subject and physician satisfaction with Blephademodex eyelid hygiene wipes * To evaluate ease of use for Blephademodex eyelid hygiene wipes * Adverse events are documented and analyzed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blephademodex

Trials testing the same drug.

NCT03987230 — Comfort Associated With The Use Of Eyelid Cleansing Products Available For The Management Of Demodex Folliculorum · NA · completed

Other Laboratoires Thea trials

Trials by the same sponsor.

NCT07169695 — A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vern · Phase 2 · recruiting
NCT07234318 — A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyc · active not recruiting
NCT07234292 — Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery. · not yet recruiting
NCT07007702 — Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Dise · completed
NCT06375499 — Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04780165 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratoires Thea
Last refreshed: 3 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04780165.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing